Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis

BACKGROUND: Hepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world’s population. Some studies have shown that adding Sofosbuvir (SOF), an HCV polymerase inhibitor to the conventional therapy of Pegylated-interferon (PegIFN) plus Ribavirin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolatimehr, Fardin, Karimi-Sari, Hamidreza, Rezaee-Zavareh, Mohammad Saeid, Alavian, Seyed Moayed, Behnava, Bita, Gholami-Fesharaki, Mohammad, Sharafi, Heidar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397824/
https://www.ncbi.nlm.nih.gov/pubmed/28427463
http://dx.doi.org/10.1186/s40199-017-0177-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397824/
https://www.ncbi.nlm.nih.gov/pubmed/28427463
http://dx.doi.org/10.1186/s40199-017-0177-x

Ejemplares similares